Khan A, Langley S J, Mullins F G, Dixon J S, Toon S
Medeval Ltd, University of Manchester.
Br J Clin Pharmacol. 1991 Oct;32(4):519-22. doi: 10.1111/j.1365-2125.1991.tb03943.x.
Ranitidine may be used at doses of up to 300 mg twice daily in the healing of duodenal ulcers, and this study investigated the potential for a pharmacokinetic or pharmacodynamic interaction between nifedipine 10 mg three times daily and ranitidine 300 mg twice daily compared with cimetidine 800 mg daily and placebo in a randomised crossover study in 18 healthy male subjects. Twelve blood samples were taken on the fifth day in each treatment period and assayed for nifedipine by h.p.l.c. Pulse, blood pressure and ECG recordings were also taken. Cimetidine, but not ranitidine, produced significant changes in the pharmacokinetics of nifedipine at steady state. Mean +/- s.d. values of AUC were 105 +/- 40 micrograms l-1 for placebo treatment, 111 +/- 45 micrograms l-1 h for ranitidine and 211 +/- 64 micrograms l-1 h for cimetidine (P less than 0.001), and Cmax values were 33 +/- 14, 39 +/- 27 and 76 +/- 40 micrograms l-1 (P less than 0.001), respectively. Neither ranitidine nor cimetidine produced statistically significant changes in the pharmacological response to nifedipine.
雷尼替丁在十二指肠溃疡愈合中可按每日两次、每次高达300毫克的剂量使用。本研究在18名健康男性受试者中进行了一项随机交叉研究,比较每日三次服用10毫克硝苯地平与每日两次服用300毫克雷尼替丁、每日服用800毫克西咪替丁及安慰剂之间药代动力学或药效学相互作用的可能性。在每个治疗期的第五天采集12份血样,采用高效液相色谱法测定硝苯地平含量。同时还记录脉搏、血压和心电图。西咪替丁而非雷尼替丁在稳态时使硝苯地平的药代动力学发生显著变化。安慰剂治疗时AUC的均值±标准差为105±40微克·升⁻¹·小时,雷尼替丁为111±45微克·升⁻¹·小时,西咪替丁为211±64微克·升⁻¹·小时(P<0.001);Cmax值分别为33±14、39±27和76±40微克·升⁻¹(P<0.001)。雷尼替丁和西咪替丁对硝苯地平的药理反应均未产生统计学上的显著变化。